Baudax Bio, Inc.
BXRX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | 0.00 |
| FCF Yield | -81.56% | -60.29% | -118.33% | -72.48% |
| EV / EBITDA | -248.66 | -176.63 | -0.32 | -1.05 |
| Quality | ||||
| ROIC | -27.24% | -136.66% | -694.34% | 147.56% |
| Gross Margin | 0.00% | -246.67% | 2,992.86% | -1,445.81% |
| Cash Conversion Ratio | 1.28 | 0.47 | 0.63 | 0.41 |
| Growth | ||||
| Revenue 3-Year CAGR | -24.45% | 1.27% | 6.47% | 37.08% |
| Free Cash Flow Growth | 29.98% | 26.11% | -24.61% | 4.22% |
| Safety | ||||
| Net Debt / EBITDA | -179.86 | -99.39 | -0.15 | -0.28 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -9.34 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -16,371.63 | -5,043.46 | -852.67 | 23.50 |